日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors

一项评估瑞戈非尼联合西妥昔单抗治疗晚期实体瘤患者的安全性和药代动力学的 1b 期研究

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.32317
Weekes, Colin; Lockhart, A Craig; Lee, James J; Sturm, Isrid; Cleton, Adriaan; Huang, Funan; Lenz, Heinz-Josef
发表日期：2019
文献求助 收藏

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers

瑞戈非尼、顺铂和培美曲塞治疗晚期非鳞状非小细胞肺癌患者的初步安全性、药代动力学和疗效

期刊:Clinical Lung Cancer
影响因子:3.3
doi:10.1016/j.cllc.2015.04.003
Hellmann, Matthew D; Sturm, Isrid; Trnkova, Zuzana Jirakova; Lettieri, John; Diefenbach, Konstanze; Rizvi, Naiyer A; Gettinger, Scott N
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report

利妥昔单抗长期单药治疗B细胞系慢性淋巴细胞白血病患者取得成功：病例报告

期刊:Journal of Medical Case Reports
影响因子:0.8
doi:10.1186/1752-1947-2-275
Sturm, Isrid; Oertel, Joachim; Oertel, Stephan; Westermann, Jörg; Pezzutto, Antonio
白血病
细胞生物学
B细胞
免疫/内分泌
发表日期：2008
文献求助 收藏

Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma

硼替佐米化疗联合体外游离轻链清除治疗多发性骨髓瘤肾管型病变

期刊:
影响因子:
doi:10.1093/ndtplus/sfm053
Bachmann, Ulrike; Schindler, Ralf; Storr, Markus; Kahl, Andreas; Joerres, Achim; Sturm, Isrid
多发性骨髓瘤
骨髓瘤
发表日期：2008
文献求助 收藏

Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy

术前放化疗治疗结直肠癌中细胞凋亡和细胞周期调控的遗传学解析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-6-124
Sturm, Isrid; Rau, Beate; Schlag, Peter M; Wust, Peter; Hildebrandt, Bert; Riess, Hanno; Hauptmann, Steffen; Dörken, Bernd; Daniel, Peter T
肿瘤
肠癌
表观遗传
肿瘤免疫
凋亡
信号转导
细胞生物学
发表日期：2006
文献求助 收藏